

European Diabetes
Epidemiology Group
(EDEG)



56th Annual Meeting

**Final Programme
& Abstract Book**

2 - 5 APRIL 2022

Creta Maris Hotel
Hersonissos, Crete

www.edeg2022.com

56th Annual Meeting of the European Diabetes Epidemiology Group (EDEG)

**Annual Meeting format
2nd / 5th April 2022**

Steering Committee EDEG

Dorte Vistisen, Chair - Copenhagen, Denmark
Konstantinos Makrilakis, Vice Chair - Athens, Greece
Francis Finucane, Secretary - Galway, Ireland
Femke Rutters, Treasurer - Amsterdam, The Netherlands
Matthias Schulze, Member - Potsdam, Germany
Jean Lawrence, Member - Bethesda, MD, USA
Stavros Liatis, ex-officio Member - Athens, Greece

Local organising committee

Konstantinos Makrilakis - Athens, Greece
Stavros Liatis - Athens, Greece
Nikolaos Kefalogiannis - Heraklion Crete, Greece
Giota Touloumi - Athens, Greece



Welcome



Dear Colleagues,

On behalf of the Steering Committee, it is a great pleasure to welcome you to the 56th annual meeting of the European Diabetes Epidemiology Group (EDEG).

The primary goals of EDEG are to lead and facilitate epidemiological research in diabetes, its risk factors and complications, and to act as a forum for collaboration, discussion and dissemination of expertise and knowledge. In this spirit, I hope you will take the opportunity to exchange and discuss research ideas, and potentially develop new collaborations.

I would like to acknowledge the great effort and perseverance of the local organizers Dr. Stavros Liatis and Prof. Konstantinos Makrilakis in organizing this event. Greece was originally supposed to host EDEG in 2020, but the meeting was cancelled due to the COVID-19 pandemic and in 2021 it was transformed into an online meeting. Now it is finally possible to hold a physical meeting and I very much hope you will contribute to making EDEG 2022 successful and enjoyable.

Sincerely,

Dorte Vistisen
Chair of EDEG

PREVIOUS EDEG MEETINGS

Dec 5 - 6, 1966 Berlin	April 29 - May 2, 1984 Vienna	March 23 - 26, 2002 Oxford
Oct 28 - 31, 1967 Zagreb, Dubrovnik	May 5 - 8, 1985 Carthago	Aug 20 - 23, 2003 Tours
Sept 25 - 26, 1968 Edinburgh	May 21 - 24, 1986 Potsdam, Berlin	April 24 - 27, 2004 Salerno
June 19 - 20, 1969 Berlin	April 12 - 15, 1987 Oxford	April 2 - 5, 2005 Siofok
June 12 - 13, 1970 Düsseldorf	May 1 - 4, 1988 Glion - sur - Montreux	May 20 - 23, 2006 Krakow
May 4 - 5, 1971 Paris	May 10 - 13, 1989 Venice Lido	March 31 - April 3, 2007 Cambridge
May 8 - 9, 1972 Bern - Riggisberg	May 20 - 23, 1990 Beer - Sheva, Israel	April 5 - 8, 2008 Helsingor
May 3 - 4, 1973 Milano	May 5 - 8, 1991 Lund	May 9 - 12, 2009 Wageningen
May 20 - 22, 1974 Lund	May 24 - 27, 1992 Bremen	May 15 - 18, 2010 Porto Heli
May 19 - 20, 1975 Stoke Poges, London	April 4 - 7, 1993 Cambridge	May 15 - 17, 2011 Jerez de la Frontera
May 6 - 8, 1976 Borovetz	May 22 - 25, 1994 Athens	May 12 - 15, 2012 Swansea
May 5 - 7, 1977 Copenhagen	May 21 - 24, 1995 Hindsgavl, Fyn	April 13 - 16, 2013 Potsdam
May 22 - 23, 1978 Kuopio	May 5 - 8, 1996 Ostuni	March 29 - April 1, 2014 Cagliari
May 30 - April 2, 1979 Corfu	May 1 - 4, 1997 Visegrad	April 25 - 28, 2015 Chantilly
May 12 - 14, 1980 Deidesheim/Pfalz	May 16 - 19, 1998 Abbaye des Vaux de Cernay	April 16 - 19, 2016 Dublin
May 14 - 16, 1981 Visegrad	May 8 - 11, 1999 Verona	May 6 - 9, 2017 Dubrovnik
May 3 - 7, 1982 Abbaye de Fontevraud	May 13 - 16, 2000 Zandvoort	April 21 - 24, 2018 Elsinore
May 1 - 4, 1983 Gargnano	May 19 - 22, 2001 Goteburg	May 11 - 14, 2019 Mondorf - Les - Bains
		April 26 - 27, 2021 Web Scientific Event

Meeting Sponsors

*We are grateful for the support we have received
for the organization of the 56th meeting of EDEG*



Programme at a Glance

Saturday 2nd April 2022

- 14.00-15.00 **Registration**
- 15.00-15.15 **Welcome address**
- 15.15-16.00 **Plenary Session 1 - Cardiovascular outcomes trials in diabetes: The idolatry of the subgroup?**
- 16.00-17.00 **Oral presentations, session I - Covid-19 disease and Diabetes**
- 17.00-17.30 *Coffee break*
- 17.30-18.30 **Oral presentations, session II - Diabetes and comorbid factors**
- 18.30-19.00 **EDEG Business meeting - General assembly**
- 19.00-20.00 **Poster session I - Diabetes in the young age**
- 20.00 *Welcome dinner*

Sunday 3rd April 2022

- 11.45-13.15 **Oral presentations, session III - Diabetes incidence**
- 13.15-14:15 *Lunch*
- 14.15-15.00 **Plenary Session 2 - The scope for a precision medicine approach to the treatment of type 2 diabetes**
- 15.00-16.15 **Poster session II - Diabetes management**
- 16.15-16.45 *Coffee break*
- 16.45-18.15 **Oral presentations, session IV - Treatment and follow-up of diabetes**
- 18.15-19.15 **Poster session III - DIABETES AND LIFESTYLE**
- 19.15 *Dinner*

Programme at a Glance

Monday 4th April 2022

- 09.15-10.00 **Plenary Session 3 - Diabetes Epidemiology in Practice**
- 10.00-11.00 **Oral presentations, session V - Burden of diabetes and its complications**
- 11.00-11.30 *Coffee break*
- 11.30-13.00 **Poster session IV - Cardiometabolic risk and incidence/prevalence of type 2 diabetes**
- 13.00-14.30 *Lunch*
- 14.30-15.15 **Plenary Session 4 - Type 2 Diabetes in Youth**
- 15.15-16.45 **Oral presentations VI - Predictors of diabetes**
- 16.45-17.15 *Coffee break*
- 17.15-18.15 **Poster session V - Complications of diabetes**
- 18.15-18.45 **Oral presentations VII - Diabetes prevalence and subtypes**
- 18.45-19.00 **Closing remarks**
- 19.30 *Gala dinner*

Final Program

Saturday 2nd April 2022

14.00-15.00 Registration

15.00-15.15 Welcome address

Chair EDEG Steering Committee: DORTE VISTISEN

Chair of the local organizing committee: STAVROS LIATIS

Professor Emeritus of Medicine, National and Kapodistrian University of Athens: NIKOLAOS KATSILAMPROS

15.15-16.00 Plenary Session 1 - Cardiovascular outcomes trials in diabetes: The idolatry of the subgroup?

Prof. APOSTOLOS TSAPAS

Chairs: DORTE VISTISEN, STAVROS LIATIS

16.00-17.00 Oral presentations, session I - Covid-19 disease and Diabetes

Chair: MARIT EIKA JØRGENSEN

- OP1** THE CLINICAL COURSE OF COVID-19 IN DIABETES PATIENTS - A NATION-WIDE MULTISTATE MODELLING COHORT STUDY
Hanan Amadid, Steno Diabetes Center Copenhagen, Denmark
- OP2** INCIDENCE OF TYPE 1 DIABETES AFTER SARS-CoV-2 INFECTION IN 123 382 CHILDREN
German Tapia, Norwegian Institute of Public Health, Norway
- OP3** RELATIONSHIP BETWEEN DIABETES AND SEVERE FORMS OF COVID-19 IN HOSPITALIZED PATIENTS: THE CORONADO CASE-CONTROL STUDY
Matthieu Wargny, Nantes University Hospital, France
- OP4** HAS THE COVID-19 PANDEMIC AFFECTED THE INCIDENCE OF TYPE 1 DIABETES? DATA FROM THE POPULATION-BASED REGISTRY OF MARCHE REGION, ITALY
Rosaria Gesuita, Centre of Epidemiology and Biostatistics, Polytechnic University of Marche, Italy

17.00-17.30 Coffee break

17.30-18.30 Oral presentations, session II - Diabetes and comorbid factors

Chair: DANIEL WITTE

- OP5** A NATIONWIDE STUDY OF THE EFFECTIVENESS OF DETECTING COLORECTAL CANCER WHEN IMPLEMENTING COLORECTAL CANCER SCREENING IN INDIVIDUALS WITH DIABETES
Tinne Laurberg, Steno Diabetes Center Aarhus, Aarhus University Hospital, Denmark
- OP6** EFFECT OF COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA ON METABOLIC OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND INSOMNIA COMPARED TO CARE AS USUAL: A RANDOMIZED CONTROLLED TRIAL
Lenka Groeneveld, Amsterdam UMC, location VUmc, The Netherlands
- OP7** QUALITY OF DIABETES CARE IN PEOPLE WITH AND WITHOUT PRIOR HOSPITALIZATION FOR SERIOUS MENTAL ILLNESS: A SCOTTISH NATIONWIDE STUDY
Stine Scheuer, Steno Diabetes Center Copenhagen, Denmark
- OP8** QUALITY OF DIABETES CARE AMONG PERSONS WITH TYPE 2 DIABETES WITH AND WITHOUT SEVERE MENTAL ILLNESS

Saturday 2nd April 2022

18.30-19.00 **EDEG Business meeting - General assembly**

Chair: DORTE VISTISEN

19.00-20.00 **Poster session I - Diabetes in the young age**

Chair: RASMUS CHRISTENSEN

- PP1** THE PRESENCE AND EXTENT OF MICROVASCULAR DISEASE IS INDEPENDENTLY ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH TYPE 1 DIABETES
Aikaterini Barmpagianni, First Department of Propaedeutic Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Greece
- PP2** EXTRA SMALL HDL PARTICLE CONCENTRATION PREDICTS INCIDENT ISCHEMIC STROKE IN TYPE 1 DIABETES
Tina Costacou, University of Pittsburgh, USA
- PP3** VITAMIN A CONSUMPTION IN PREGNANCY AND RISK OF OFFSPRING TYPE 1 DIABETES
Nicolai A. Lund-Blix, Norwegian Institute of Public Health, Norway
- PP4** EFFECTS OF PUMP TREATMENT ON ENDOTHELIAL GLYCOCALYX AND CARDIOVASCULAR FUNCTION COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 1 DIABETES: IMPROVEMENT AFTER A SIX-MONTH TREATMENT
Aikaterini Kountouri, General University Attikon Hospital, Greece
- PP5** FERTILITY AMONG WOMEN WITH TYPE 1 OR TYPE 2 DIABETES
Gunnar Toft, Steno Diabetes Center Aarhus, Aarhus University Hospital, Denmark
- PP6** ASSOCIATIONS OF BIRTH WEIGHT WITH BODY COMPOSITION AND CARDIOMETABOLIC RISK. MARKERS IN CHILDREN AGED 8-12 YEARS: THE IABC STUDY
Soboka Megersa Bikila, University of Copenhagen, Denmark

20.00 *Welcome dinner*

Sunday 3rd April 2022

11.45-13.15 Oral presentations, session III - Diabetes incidence

Chair: SARAH WILD

- OP9** DIFFERENTIAL IMPACT OF FAMILY HISTORY OF TYPE 1 DIABETES ON INCIDENCE OF ISLET AUTOIMMUNITY AND PROGRESSION TO CLINICAL TYPE 1 DIABETES: THE MIDIA STUDY
Lars C. Stene, Norwegian Institute of Public Health, Norway
- OP10** LOW BIRTH WEIGHT IS ASSOCIATED WITH A NON-GENETIC HIGHER INCIDENCE RATE OF TYPE 2 DIABETES
Rasmus Wibaek, Steno Diabetes Center Copenhagen, Denmark
- OP11** MATERNAL SMOKING DURING PREGNANCY AND TYPE 1 DIABETES IN THE OFFSPRING: A NATIONWIDE REGISTER-BASED STUDY WITH FAMILY-BASED DESIGNS
Yuxia Wei, Karolinska Institutet, Sweden
- OP12** PLASMA IMMUNOGLOBULIN G N-GLYCOSYLATION PATTERNS ARE ASSOCIATED WITH INCIDENT TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE: EPIC-POTSDAM STUDY
Anna Birukov, German Institute of Human Nutrition Potsdam-Rehbruecke, Germany
- OP13** TRENDS IN TYPE 1 DIABETES INCIDENCE IN SCOTLAND BETWEEN 2006 AND 2019
Sarah Wild, University of Edinburgh, United Kingdom
- OP14** INTERACTION BETWEEN DAIRY PRODUCT INTAKE OR PHOSPHOLIPID ODD CHAIN FATTY ACIDS AND GAD65 AUTOANTIBODIES ON THE INCIDENCE OF ADULT-ONSET DIABETES
Anna-Maria Lampousi, Institute of Environmental Medicine, Karolinska Institutet, Sweden

13.15-14:15 *Lunch*

14.15-15.00 **Plenary Session 2 - The scope for a precision medicine approach to the treatment of type 2 diabetes**

Dr. JOHN DENNIS

Chairs: MATTHIAS SCHULZE, FRANCIS FINUCANE

15.00-16.15 Poster session II - Diabetes management

Chair: INA DANQUAH

- PP7** PATTERNS OF REFERRAL, PATIENT PATHWAYS AND CHANGES IN HBA1C IN SPECIALIST CARE FOR PATIENTS WITH TYPE 2 DIABETES
Kjersti Nøkleby, *University of Oslo, Norway*
- PP8** THE EFFECT OF THREE-MONTH TREATMENT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS OR SODIUM-GLUCOSE CONTRASPORTER-2 INHIBITORS ON ENDOTHELIAL AND VASCULAR FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND STROKE
Aikaterini Kountouri, *General University Attikon Hospital, Greece*
- PP9** COMPARING DIABETES CARE OUTCOMES OF THE CENTRALLY ORGANIZED HOORN. DIABETES CARE SYSTEM WITH REGULAR CARE BY GENERAL PRACTITIONERS IN THE NETHERLANDS
Marieke Blom, *Amsterdam UMC, Vrije Universiteit Amsterdam, Department of General Practice, Amsterdam Public Health research institute, The Netherlands*
- PP10** THE EFFECT OF COMBINED DULAGLUTIDE-DAPAGLIFLOZIN TREATMENT VS DPP-4 INHIBITORS ON ARTERIAL STIFFNESS AND ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Emmanouil Korakas, *Second Department of Internal Medicine and Research Institute, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Greece*
- PP11** VALIDATION OF AN ANNOUNCED TELEPHONE PILL COUNT COMPARED TO A HOME-VISIT PILL COUNT IN PEOPLE WITH TYPE 2 DIABETES OR CARDIOVASCULAR DISEASE
Marlous Langendoen-Gort, *Amsterdam UMC, Vrije Universiteit Amsterdam, Department of General Practice, Amsterdam Public Health Research Institute, The Netherlands*
- PP12** THE DIABETES, MANAGEMENT AND TREATMENT (DIAMANT) COHORT: A DYNAMIC PROSPECTIVE COHORT OF PATIENTS WITH DIABETES TREATED IN PRIMARY CARE IN THE NETHERLANDS
Karin Swart, *PHARMO Institute for Drug Outcomes Research, The Netherlands*
- PP13** A BAYESIAN SEMI-PARAMETRIC APPROACH TO HANDLE MISSING DATA WITH APPLICATION TO A TREATMENT SELECTION MODEL IN TYPE 2 DIABETES
John Dennis, *University of Exeter, United Kingdom*
- PP14** CARDIOMETABOLIC EFFECTS OF PHARMACEUTICAL TREATMENT FOR OBESITY: 3 MONTHS DATA FROM A PROSPECTIVE STUDY OF NALTREXONE/BUPROPION VS. LIRAGLUTIDE 3 MG ADMINISTRATION IN PATIENTS WITH INCREASED BODY WEIGHT
Georgia Argyrakopoulou, *Diabetes and Obesity Unit, Athens Medical Center, Greece*
- PP15** PATIENT-REPORTED OUTCOME MEASURES FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW
Femke Rutters, *Department of Epidemiology & Biostatistics, Amsterdam University Medical Center, the Netherlands*

16.15-16.45 Coffee break

16.45-18.15 Oral presentations, session IV - Treatment and follow-up of diabetes

Chair: ALEXANDROS KOKKINOS

- OP15** TRAJECTORIES OF CLINICAL CHARACTERISTICS, TREATMENT CHOICES, AND COMPLICATIONS IN DATA-DRIVEN SUBGROUPS OF TYPE 2 DIABETES
Xinyu Li, University of Groningen, The Netherlands
- OP16** STENO-2 IMPACT STUDY: DOES THE SUCCESS OF STENO-2 TRIAL LED TO A CHANGE IN CLINICAL PRACTICE IN TREATING TYPE 2 DIABETES PATIENTS WITH MICROALBUMINURIA USING MULTIFACTORIAL PHARMACOLOGICAL INTERVENTION?
Lam Opal Huang, *Steno Diabetes Center Copenhagen, Denmark*
- OP17** SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AS ADJUNCT THERAPY FOR TYPE 1 DIABETES AND THE BENEFIT ON CARDIOVASCULAR AND RENAL DISEASE EVALUATED BY STENO RISK ENGINES
Elisabeth Buur Stougaard, *Steno Diabetes Center Copenhagen, Denmark*
- OP18** FACTORS AFFECTING CONTINUOUS PARTICIPATION IN FOLLOW-UP EVALUATIONS DURING A LIFESTYLE INTERVENTION PROGRAM TO PREVENT TYPE 2 DIABETES: THE FEEL4DIABETES-STUDY
Elias Kourpas, *University of Delaware, USA*
- OP19** SETTING THE OPTIMAL SCREENING INTERVAL FOR DIABETIC RETINOPATHY USING AN INDIVIDUALIZED APPROACH
Lars Jorge Diaz, *Steno Diabetes Center Copenhagen, Denmark*
- OP20** THE ASSOCIATION BETWEEN PRE-RAMADAN DIABETES EDUCATION AND METABOLIC PARAMETERS IN MUSLIMS WITH TYPE 2 DIABETES: A RETROSPECTIVE STUDY
Siham Bouchareb, *Department of General Practice, Amsterdam Public Health research institute, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands*

18.15-19.15 Poster session III - DIABETES AND LIFESTYLE

Chair: KRISTINE FAERCH

- PP16** ADHERENCE TO THE DUTCH HEALTHY DIET INDEX AND CHANGE IN GLYCEMIX CONTROL AND CARDIOMETABOLIC MARKERS IN PEOPLE WITH TYPE 2 DIABETES
Joline Beulens, Amsterdam UMC, The Netherlands
- PP17** PHYSICAL ACTIVITY AND DIASTOLIC DYSFUNCTION IN PEOPLE WITH TYPE 2 DIABETES
Anna Hoek, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology & Data Science, The Netherlands
- PP18** CHANGES IN OBJECTIVELY MEASURED PHYSICAL ACTIVITY ENERGY EXPENDITURE DURING A STRUCTURED AEROBIC EXERCISE INTERVENTION IN HEALTHY OLDER ADULTS: THE HERTFORDSHIRE PHYSICAL ACTIVITY TRIAL
Francis Finucane, National University of Ireland Galway, Ireland
- PP19** A COMPREHENSIVE LIFESTYLE INDEX AND ITS ASSOCIATIONS WITH DNA METHYLATION AND TYPE 2 DIABETES AMONG GHANAIAI ADULTS UNDER TRANSITION: THE RODAM STUDY
Carol Abidha, Heidelberg Institute of Global Health, Heidelberg University Hospital, Germany
- PP20** LOW-CARB, HIGH-FAT DIET AND ASSOCIATIONS WITH GLYCAEMIC CONTROL AND DIABETIC COMPLICATIONS AMONG GHANAIAIS: THE RODAM STUDY
Tracy B Osei, Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg University, Germany
- PP21** SYSTEMATIC REVIEW OF DIET QUALITY SCORES INCLUDING DIET DIVERSITY IN RELATION TO TYPE 2 DIABETES AMONG OTHER CHRONIC DISEASES AND MORTALITY IN HEALTHY ADULTS
Daniela Nickel, Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Germany
- PP22** THE INTERACTION BETWEEN THE COMMUNITY FOOD ENVIRONMENT AND COOKING SKILLS IN RELATION TO DIET-RELATED OUTCOMES
Noreen Siddiqui, Amsterdam UMC, location VUmc, The Netherlands
- PP23** THE ASSOCIATION OF VITAL EXHAUSTION AND BURNOUT WITH THE METABOLIC SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS
Sanne Kremers, Amsterdam University Medical Centre, location VU medical Centre, Department of Epidemiology and Datascience, The Netherlands
- PP24** THE ASSOCIATION BETWEEN SOCIAL JETLAG AND THE METABOLIC SYNDROME AND TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Emma Bouman, Amsterdam UMC, The Netherlands

19.15 *Dinner*

Monday 4th April 2022

09.15-10.00 Plenary Session 3 - Diabetes Epidemiology in Practice

Prof. GIEL NIJPELS

Chairs: KONSTANTINOS MAKRILAKIS, FEMKE RUTTERS

10.00-11.00 Oral presentations, session V - Burden of diabetes and its complications

Chair: MARIEKE BLOM

- OP21** CLINICAL CHARACTERISTICS ASSOCIATED WITH SUDDEN CARDIAC ARREST IN PEOPLE WITH TYPE 2 DIABETES: A CASE-CONTROL STUDY ON PRIMARY CARE DATA
Peter Harms, Amsterdam UMC, The Netherland
- OP22** MEN WITH YOUNG ONSET TYPE 2 DIABETES DEVELOP RETINOPATHY AT AN EARLIER AGE AND SOONER AFTER DIAGNOSIS THAN WOMEN
Katrina Tibballs, Department of General Practice, Institute of Health and Society, Faculty of Medicine, University of Oslo, Norway
- OP23** CARDIOVASCULAR COMPLICATIONS IN TYPE 2 DIABETES BEFORE AND AFTER DIAGNOSIS: IMPACT ON EXPECTED LIFETIME AND TRENDS 1996-2020
Kim Katrine Bjerring Clemmensen, Steno Diabetes Center Copenhagen, Denmark
- OP24** HUGE INCREASE IN DKA AND SEVERE DKA AT THE ONSET OF TYPE 1 DIABETES IN ITALY IN 2020: A SILENT EPIDEMIC
Valentino Cherubini, Department of Women's and Children's Health Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy

11.00-11.30 Coffee break

11.30-13.00 Poster session IV - Cardiometabolic risk and incidence/prevalence of type 2 diabetes

Chair: TINA COSTACOU

- PP25** PLASMA INDUSTRIAL AND RUMINANT TRANS FATTY ACIDS AND INCIDENT TYPE 2 DIABETES IN THE EPIC-POTSDAM COHORT
Matthias Schulze, Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Germany
- PP26** GENDER DIFFERENCES IN SCREENING FOR GLUCOSE PERTURBATIONS, CARDIOVASCULAR RISK FACTOR MANAGEMENT, AND PROGNOSIS IN PATIENTS WITH CORONARY ARTERY DISEASE AND DYSGLYCAEMIA
Jaakko Tuomilehto, Finnish Institute for Health and Welfare, Finland
- PP27** TRENDS IN THE PREVALENCE AND INCIDENCE OF PREDIABETES AMONG IMMIGRANTS IN ONTARIO, CANADA, 2011-2017
Ghazal Fazli, Unity Health Toronto, Canada
- PP28** TYPE 2 DIABETES, THE EPIDEMIC: TRENDS IN PREVALENCE, TREATMENT AND RISK-FACTOR CONTROL, 2004-2019
Jetty Overbeek, PHARMO Institute for Drug Outcomes Research, The Netherlands
- PP29** PLASMA RETINOL AND RETINOL BINDING PROTEIN 4 LEVELS AND RISK OF CARDIOVASCULAR DISEASES AND TYPE 2 DIABETES
Catarina Schiborn, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany

Monday 4th April 2022

- PP30** BODY MASS INDEX AND OBESITY: ACCURACY AND PREDICTION BASED ON SELF-REPORTED WEIGHT AND HEIGHT IN A NATIONWIDE HEALTH EXAMINATION SURVEY IN GREECE
Nikos Pantazis, *Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece*
- PP31** THE ENTERO-ENDOCRINE RESPONSE FOLLOWING A MIXED-MEAL CHALLENGE WITH A NON-NUTRITIVE PRE-LOAD IN PARTICIPANTS WITH PRE-DIABETES AND TYPE 2 DIABETES: A CROSSOVER RANDOMIZED CONTROLLED TRIAL
Mirthe Mulwijk, *Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology & Data Science, The Netherlands*
- PP32** OBESITY IN ADULTS LIVING IN GREECE: PREVALENCE, FACTORS ASSOCIATED WITH AND ITS CONTRIBUTION TO CARDIOVASCULAR RISK FACTORS' CLUSTERING
Giota Touloumi, *Dept. of Hygiene, Epidemiology & Medical Statistics, Medical School, National & Kapodistrian University of Athens, Greece*
- PP33** BODY MASS INDEX AND PREVALENCE OF OBESITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. A COMPARISON OVER THE LAST 20 YEARS
Stamatia Simati, *First Department of Propaedeutic Medicine, Diabetes Center, Laiko Hospital, Medical School, National & Kapodistrian University of Athens, Greece*
- PP34** DIABETES MELLITUS TYPE 2 AND OTHER MODIFIABLE RISK FACTORS AMONG PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME IN A TERTIARY HOSPITAL DURING ONE-YEAR PERIOD
Chris Siafarikas, *Laiko General Hospital of Athens, Greece*
- PP35** PREDICTING SUDDEN CARDIAC DEATH IN THE GENERAL POPULATION: VALIDATION OF A PREDICTION MODEL FOR THE OCCURRENCE OF SUDDEN CARDIAC DEATH IN THE GENERAL POPULATION: THE ESCAPE-NET PROJECT
Sabrina Welten, *Amsterdam Public Health research institute, The Netherlands*

13.00-14.30 *Lunch*

Monday 4th April 2022

14.30-15.15 Plenary Session 4 - Type 2 Diabetes in Youth

Prof. DANA DABELEA

Chairs: JEAN LAWRENCE, GREGERS STIG ANDERSEN

15.15-16.45 Oral presentations VI - Predictors of diabetes

Chair: GIOTA TOULOUMI

- OP25** DNA METHYLATION MEDIATES THE RELATIONSHIP BETWEEN FAMILY HISTORY OF TYPE 1 DIABETES (T1D) AND T1D RISK: THE DIABETES AUTOIMMUNITY STUDY IN THE YOUNG (DAISY)
Jill Norris, Colorado School of Public Health, USA
- OP26** METABOLOMIC PREDICTORS OF DYSGLYCEMIA IN TWO YOUTH COHORTS: EXPLORING PERINATAL OUTCOMES AMONG CHILDREN AND PROJECT VIVA
Wei Perng, Colorado School of Public Health, USA
- OP27** ASSOCIATIONS BETWEEN PARENTAL BMI AND OFFSPRING BMI TRAJECTORIES-POTENTIAL EFFECT MODIFICATION BY GRANDPARENTAL SOCIO-ECONOMIC POSITION
Jie Zhang, Aarhus University, Denmark
- OP28** DOMAIN OF PHYSICAL ACTIVITY MATTERS FOR RISK OF TYPE 2 DIABETES
Jeroen van der Velde, Department of clinical epidemiology, Leiden University Medical Center, The Netherland
- OP29** ASSOCIATIONS OF LONGITUDINAL CHANGES OF DIETARY PATTERNS AND RISK OF TYPE 2 DIABETES AND CARDIOVASCULAR DISEASES IN THE EPIC-POTSDAM STUDY
Franziska Jannasch, Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Germany
- OP30** INTERACTION BETWEEN TOBACCO USE AND TYPE 2 GENETIC SUSCEPTIBILITY IN THE RISK OF T2D AND LADA
Jessica Edstorp, Karolinska Institutet, Sweden

16.45-17.15 Coffee break

17.15-18.15 Poster session V - Complications of diabetes

Chair: MIRTHE MUILWIJK

- PP36** INTERLEUKIN 6 AND INCIDENT HEART FAILURE IN PERSONS WITH TYPE 2 DIABETES: THE HOORN DIABETES CARE SYSTEM COHOR
Sharon Remmelzwaal, Department of Epidemiology & Data Science, Amsterdam Public Health Research Institute, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands
- PP37** DYSGLYCAEMIA IS ASSOCIATED WITH LOW BLOOD OXYGEN SATURATION IN INDIVIDUALS WITH AND WITHOUT DIABETES OR PREDIABETES: A CROSS-SECTIONAL STUDY IN THE LOLLAND-FALSTER HEALTH STUDY COHORT
Jens Christian Laursen, Steno Diabetes Center Copenhagen, Denmark
- PP38** DEVELOPMENT IN KIDNEY FUNCTION AMONG PEOPLE WITH DIABETES AND NEPHROPATHY: A RETROSPECTIVE COHORT STUDY
Kristin Jesse, Steno Diabetes Center Copenhagen, Denmark

Monday 4th April 2022

- PP39** INCIDENCE AND PREVALENCE OF DIABETIC RETINOPATHY IN THE GREENLANDIC INUIT: A REGISTER-BASED STUDY
Trine Jul Larsen, University of Greenland, Ilisimatusarfik, Nuuk, Greenland
- PP40** EFFECT OF THE SECOND COVID-19-ASSOCIATED LOCKDOWN ON THE METABOLIC CONTROL OF PATIENTS WITH TYPE 2 DIABETES IN GREECE
Eleftheria Papachristoforou, First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece
- PP41** KIDNEY FUNCTION AND RISK OF DEMENTIA: OBSERVATIONAL STUDY, META-ANALYSIS AND TWO-SAMPLE MENDELIAN RANDOMIZATION STUDY
Daniel Witte, Steno Diabetes Center Aarhus, Denmark
- PP42** SEX-DIFFERENCES IN DEPRESSIVE SYMPTOMS AND DIABETES IN MEXICO. FINDINGS FROM ENSANUT 2018-19
Omar Silverman-Retana, Aarhus University, Steno Diabetes Center Aarhus and Danish Diabetes Academy, Denmark
- PP43** THE IMPACT OF COUNTRY OF BIRTH ON DEVELOPMENT OF DIABETIC LATE COMPLICATIONS IN YOUNGER ADULTS WITH EARLY-ONSET TYPE 2 DIABETES: A REGISTRY-BASED STUDY
Kristine Stoltenberg Addington, Steno Diabetes Center Copenhagen, Denmark

18.15-18.45 **Oral presentations VII - Diabetes prevalence and subtypes**

Chair: JAAKKO TUOMILEHTO

- OP31** PREVALENCE OF UNDIAGNOSED DIABETES IN POPULATION-BASED STUDIES BY NATIONAL HEALTH AND ECONOMIC METRICS: A SYSTEMATIC REVIEW
Paz Lopez-Doriga Ruiz, Department of Chronic Diseases, Norwegian Institute of Public Health, Norway
- OP32** NOVEL SUBGROUPS OF ADULT-ONSET DIABETES IN GHANAIAN POPULATIONS. A DATA-DRIVEN CLUSTER ANALYSIS WITH CLINICAL VARIABLES
Ina Danquah, Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg University, Germany

18.45-19.00 **Closing remarks**

KONSTANTINOS MAKRILAKIS, DORTE VISTISEN

19.30 *Gala dinner*

Tuesday 5th April 2022

Check-out and departures

INVITED SPEAKERS



DANA DABELEA

MD, PhD, Conrad M. Riley Professor of Epidemiology and Pediatrics, Director, LEAD Center, Colorado School of Public Health, Anschutz Medical Campus

Type 2 Diabetes in Youth

Dr. Dabelea, MD, PhD is the Director of the Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center at the University of Colorado Anschutz Medical Campus, and a University Distinguished Professor of Epidemiology and Pediatrics. She is a leader in studies of pediatric diabetes, both type 1 and type 2, focusing on the role of the prenatal and postnatal environmental and behavioral factors contributing to childhood obesity and diabetes, and their consequences throughout the lifespan. Dr. Dabelea has a record of engaging and mentoring students, fellows and junior faculty across many research projects. Dr. Dabelea is a recipient of the American Diabetes Association Kelly West Award for Epidemiology, the Lilienfeld Award from the American College of Epidemiology and the Elizabeth D. Gee Memorial Lectureship Award from, which recognizes and honors an outstanding faculty member of the University of Colorado for efforts to advance women in academia, interdisciplinary scholarly contributions, and distinguished teaching. She received her MD degree (1990) and her PhD degree in Clinical Sciences (1997) from the University of Medicine and Pharmacy Timisoara, Romania.



JOHN DENNIS

PhD, Senior Research Fellow, University of Exeter Medical School. John is an Senior Independent Research Fellow, funded by a UKRI E3 Independent Research Fellowship.

The scope for a precision medicine approach to the treatment of type 2 diabetes

John's research focuses on developing a personalized or 'precision' approach to drug therapy in type 2 diabetes, a condition for which there are many different drug options but little guidance to help clinicians and patients choose between them. John is applying data science and advanced statistical methods to better understand the benefits and risks of each drug option, and to develop a decision aid to help health professionals choose the best drug for their individual patients.

John is also developing a more general methodological framework for precision medicine research combining data from UK routine primary care (CPRD) and randomised clinical trials.

He completed his PhD in Medical Statistics under Professor William Henley, Dr Beverley Shields and Professor Andrew Hattersley. He was awarded runner-up in the Diabetes UK Type 2 Diabetes Research Prize in 2017 and won the Diabetes UK Lily Clinical Science Poster Award in 2015. Prior to joining the Diabetes team at Exeter, John trained at the London School of Hygiene & Tropical Medicine and worked as an epidemiological researcher in the financial services industry, specializing in longevity modelling.

INVITED SPEAKERS



GIEL NIJPELS

Professor Emeritus, APH - Health Behaviors & Chronic Diseases, Visiting Fellow, General Practice/Family Medicine, University Medical Centers, Amsterdam Umc

Diabetes Epidemiology in Practice

Giel Nijpels (1949, Alkmaar, the Netherlands) studied medicine at the University of Amsterdam and specialized as a general practitioner. In 1989 he was one of the initiators of the Hoorn Study. In 1996 he started the Diabetes Care System West-Friesland, one of the first diabetes management models in the Netherlands. Giel Nijpels is emeritus professor of General Practice at the Amsterdam University Medical Centers Amsterdam. He was project leader of several scientific projects on the epidemiology and pathophysiology of type 2 diabetes and projects on diabetes prevention and diabetes care programmes and projects on integrated care for home-living elderly people.

Number of publications: 683. Number of citations: 24729. His H-index is 73.



APOSTOLOS TSAPAS

Professor of Medicine and Diabetes, Director of the Second Medical Department, Aristotle University Thessaloniki, Cruddas Link Fellow, Harris Manchester College, University of Oxford

Cardiovascular outcomes trials in diabetes: The idolatry of the subgroup?

Dr. Apostolos Tsapas is Professor of Medicine at Aristotle University Thessaloniki, and head of the Diabetes Centre, Second Medical Department at Ippokraton General Hospital, Thessaloniki, Greece. He is also lead investigator at the Clinical Research and Evidence-Based Medicine Unit at Aristotle University (cebm.med.auth.gr), and senior research fellow at Harris Manchester College, University of Oxford, UK. Dr. Tsapas earned his MD and PhD degrees from the Aristotle University Thessaloniki. He also earned an MSc degree in evidence-based healthcare from the Centre for Evidence Based Medicine (CEBM) at the University of Oxford. Dr. Tsapas completed a fellowship at the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) in UK. In 2011 he worked for six months as visiting scientist in the Knowledge and Evaluation Research Unit at Mayo Clinic, Rochester MN. Dr. Tsapas has been involved in the development of the Hellenic diabetes guidelines, and the joined American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) 2012 and 2015 position statements on the management of hyperglycaemia in type 2 diabetes. He has also co-authored more than 60 full text papers in peer reviewed journals with over 2500 citations, including several systematic reviews and meta-analyses on a broad range of therapeutic and diagnostic interventions in diabetes in high impact journals. His main research interests include knowledge synthesis (systematic reviews and meta-analyses), evidence-based practice, and clinical decision making in medicine and diabetes.

CHAIRS

GREGERS STIG ANDERSEN

Steno Diabetes Center Copenhagen, Denmark

MARIEKE BLOM

amsterdam umc, location vumc, department of general practice, the Netherlands

RASMUS CHRISTENSEN

Steno Diabetes Center Copenhagen, Gentofte, Denmark

TINA COSTACOU

University of Pittsburgh, USA

INA DANQUAH

University of heidelberg, institute of global health, Germany

KRISTINE FAERCH

Steno Diabetes Center Copenhagen, Denmark

FRANCIS FINUCANE

Galway University Hospitals, Ireland

MARIT EIKA JØRGENSEN

Steno Diabetes Center Copenhagen, Denmark

ALEXANDROS KOKKINOS

General Hospital of Athens "Laiko", Greece

JEAN LAWRENCE

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, USA

STAVROS LIATIS

General Hospital of Athens "Laiko", Greece

KONSTANTINOS MAKRILAKIS

General Hospital of Athens "Laiko", Greece

MIRTHE MUILWIJK

Epidemiology and datascience, amsterdam public health, vrije universiteit, amsterdam umc, the netherlands

FEMKE RUTTERS

Amsterdam University Medical Center, the Netherlands

MATTHIAS SCHULZE

German Institute of Human Nutrition Potsdam-Reh-
bruecke, Germany

GIOTA TOULOUMI

Department of Hygiene, Epidemiology & Medical Statis-
tics, Medical School, National & Kapodistrian University
of Athens

JAAKKO TUOMILEHTO

Finnish Institute for Health and Welfare, Finland

DORTE VISTISEN

Steno Diabetes Center Copenhagen, Clinical Research,
Denmark

SARAH WILD

The University of Edinburgh, United Kingdom

DANIEL WITTE

Aarhus University, Denmark